Frida Therapeutics Trademark Intent to Use Application
Summary
The USPTO has received an intent-to-use trademark application from Frida Therapeutics for services related to pharmaceutical research and development. The application covers R&D for new pharmaceutical products and treatments for autoimmune, inflammatory, and allergic diseases.
What changed
The United States Patent and Trademark Office (USPTO) has recorded an intent-to-use trademark application (TM99722602) filed on March 24, 2026, by Frida Therapeutics. The application seeks to register a trademark for services including pharmaceutical research and development, R&D of new pharmaceutical products, and R&D for the treatment of autoimmune, inflammatory, and allergic diseases.
This filing represents a new trademark application and does not impose any immediate compliance obligations on regulated entities. It signifies Frida Therapeutics' intent to use the mark in commerce for the specified services. Compliance officers in the pharmaceutical and biotechnology sectors may note this as a development in the competitive landscape.
Source document (simplified)
← USPTO Trademark Applications
FRIDA THERAPEUTICS
Intent to Use TM99722602 Kind: intenttouse Mar 25, 2026
Abstract
Pharmaceutical research and development; Research and development services of new pharmaceutical products; Research and development in the pharmaceutical and biotechnology fields; research and development services for the treatment of autoimmune, inflammatory, and allergic diseases
Filing Date
2026-03-24
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Telecom & Technology alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Trademarks - Technology Services (Class 042) publishes new changes.